Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)
Frequently Asked Questions About Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)
Does Syndax Pharmaceuticals focus on any specific types of cancer?
Yes, Syndax Pharmaceuticals has a particular emphasis on treating various forms of cancer, including breast cancer, leukemia, and solid tumors. Their research is geared towards developing therapies that target these malignancies effectively.
Has Syndax Pharmaceuticals received any partnerships?
Yes, Syndax Pharmaceuticals has entered into partnerships and collaborations with various pharmaceutical companies and research institutions to advance their drug development programs, allowing for shared expertise and resources in tackling complex diseases.
How does Syndax Pharmaceuticals prioritize research?
Syndax Pharmaceuticals prioritizes research based on unmet medical needs, potential market opportunities, and the scientific rationale for their drug candidates. This strategy ensures that their focus aligns with areas that can greatly benefit patients.
Is Syndax Pharmaceuticals publicly traded?
Yes, Syndax Pharmaceuticals is a publicly traded company listed on the Nasdaq under the ticker symbol SNDX. This status allows them to raise capital through the sale of stock to fund their drug development efforts.
What are the recent developments for Syndax Pharmaceuticals?
Recent developments for Syndax Pharmaceuticals include advancements in their clinical pipeline with ongoing clinical trials for their investigational products, presentations at scientific conferences, and updates on partnerships and collaborations that support their research initiatives.
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of cancer and other serious diseases. The company specializes in building a pipeline of novel cancer therapies aimed at enhancing the immune response to tumors and targeting specific molecular pathways.
What drugs is Syndax Pharmaceuticals developing?
Syndax's most notable drug candidates include entinostat, an investigational treatment for various types of cancer, and axatilimab, an anti-CSF-1R monoclonal antibody. These drugs are in various stages of clinical trials, targeting specific cancer pathways.
What is axatilimab?
Axatilimab is an investigational monoclonal antibody that targets colony-stimulating factor 1 receptor (CSF-1R), with potential applications in treating cancers and autoimmune diseases. Its mechanism is aimed at modifying the tumor microenvironment to improve patient outcomes.
What is entinostat used for?
Entinostat is being developed as a treatment for cancer, particularly focusing on breast cancer and other solid tumors. It is designed to enhance the immune system's response to cancer cells and improve the effectiveness of existing therapies.
What is Syndax's approach to drug development?
Syndax Pharmaceuticals adopts a science-driven approach to drug development, focusing on understanding the underlying mechanisms of disease and leveraging this knowledge to create innovative therapies. Collaboration with academic institutions and industry partners enhances their capabilities in research.
What is the goal of Syndax Pharmaceuticals?
The primary goal of Syndax Pharmaceuticals is to develop and commercialize novel therapies that improve the lives of patients with cancer and other serious diseases. They aim to provide more effective treatment options and enhance patient outcomes.
What is the significance of CSF-1R in cancer treatment?
CSF-1R plays a crucial role in the regulation of the immune response within the tumor microenvironment. Targeting this receptor, as done with axatilimab, has the potential to enhance anti-tumor immunity and inhibit tumor growth, making it a significant area of focus for cancer therapies.
What is the ticker symbol for Syndax Pharmaceuticals?
Syndax Pharmaceuticals is traded on the Nasdaq exchange under the ticker symbol 'SNDX'.
What kind of clinical trials is Syndax conducting?
Syndax conducts Phase 1 and Phase 2 clinical trials to evaluate the safety, efficacy, and pharmacokinetics of their drug candidates. These trials involve various patient populations and are designed to gather critical data to support regulatory submissions.
When was Syndax Pharmaceuticals founded?
Syndax Pharmaceuticals was founded in 2008 with the aim of developing innovative therapies for cancer treatment, positioning itself as a key player in the oncology field.
Where is Syndax Pharmaceuticals headquartered?
Syndax Pharmaceuticals is headquartered in Cary, North Carolina. This location supports the company's research and development efforts and provides access to a network of pharmaceutical and biotech experts.
Who are the key executives at Syndax Pharmaceuticals?
The leadership team at Syndax Pharmaceuticals includes experienced individuals from the biopharmaceutical industry, including the CEO and other key executives who bring substantial scientific and operational expertise to guide the company's strategic direction.
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 12.56
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 1:12 pm EDT on April 3rd, 2025
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 872.72M
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 69.48M shares outstanding.